GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (STU:61Y) » Definitions » Loans Receivable

Marinus Pharmaceuticals (STU:61Y) Loans Receivable : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Marinus Pharmaceuticals Loans Receivable?

Marinus Pharmaceuticals's Loans Receivable for the quarter that ended in Sep. 2024 was €0.00 Mil.


Marinus Pharmaceuticals Loans Receivable Historical Data

The historical data trend for Marinus Pharmaceuticals's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals Loans Receivable Chart

Marinus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Marinus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Marinus Pharmaceuticals Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Marinus Pharmaceuticals Loans Receivable Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Marinus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Marinus Pharmaceuticals Headlines

No Headlines